Share Price
Ticker: KDEV List: NASDAQ OMX
Volume:
CEO commenting year-end report 2017 (Swedish)
Press Releases
-
2018-04-16
Karolinska Development's portfolio company Aprea presents initial results from the ongoing phase Ib/II study with APR-246 and azacitidine for the treatment of Mutant Myelodysplastic Syndromes
-
2018-04-13
Karolinska Development sells remaining shares in BioArctic
-
2018-03-21
Karolinska Development Annual Report 2017 published
News
-
2018-04-18
Karolinska Development's portfolio company Modus Therapeutics' sevuparin granted Rare Pediatric Disease Designation from FDA for the treatment of sickle cell disease
-
2018-04-06
Asarina Pharma announces the start of a clinical Phase IIB study in patients with premenstrual dysphoric disorder
-
2018-03-19
Karolinska Development's portfolio company Forendo Pharma granted a €3 million loan
